No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

byKathleen Lau

September 16, 2021

in StudyGraphics

Detection of pathogenic genetic variants in early-onset atrial fibrillation

RelatedReports

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026

Pediatric palliative care outcome measures often miss quality of life

Pediatrics

Isotonic Fluids Reduce Hyponatremia in Hospitalized Children

February 4, 2026

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Oncology

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

January 28, 2026

Reduced venous recanalization after acute deep vein thrombosis associated with post-thrombotic syndrome

Chronic Disease

Effect of high elevation on deep vein thrombosis: a multicenter cohort study

January 22, 2026

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Camrelizumab with chemotherapy demonstrated improved overall survival and progression-free survival of esophageal squamous cell carcinoma patients versus placebo

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Mental health in young adults may be linked to sleep chronotype

#Visual Abstract Watchful waiting may be an appropriate strategy for some patients with basal cell carcinomas

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports